Dimple Pandya

Title: Dimple Pandya: Innovator in Cancer Therapy

Introduction

Dimple Pandya is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of cancer therapy, particularly in the treatment of pancreatic cancer. His innovative approach combines specific antibodies to enhance treatment efficacy.

Latest Patents

Dimple Pandya holds a patent for a groundbreaking invention titled "Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer." This patent relates to methods of treating pancreatic cancer using particular dosage regimes of antibodies that bind to the colony stimulating factor 1 receptor (CSF1R), such as cabiralizumab, in combination with antibodies that bind to programmed cell death 1 (PD-1), like nivolumab. He has 1 patent to his name.

Career Highlights

Throughout his career, Dimple has worked with prominent companies in the pharmaceutical industry. He has been associated with Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company, where he has contributed to advancing cancer treatment methodologies.

Collaborations

Dimple has collaborated with esteemed colleagues, including Katherine E. Lewis and Serena Kimi Perna. These partnerships have further enriched his research and development efforts in the field of oncology.

Conclusion

Dimple Pandya's innovative work in cancer therapy exemplifies the impact of combining advanced scientific approaches to improve treatment outcomes. His contributions are paving the way for new therapeutic strategies in the fight against pancreatic cancer.